Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to “Sell”

Pulse Biosciences (NASDAQ:PLSE) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research note issued to investors on Thursday.

Pulse Biosciences Stock Performance

Shares of PLSE opened at $18.58 on Thursday. The stock has a 50-day simple moving average of $11.35 and a 200-day simple moving average of $9.74. The stock has a market capitalization of $1.03 billion, a PE ratio of -22.94 and a beta of 1.75. Pulse Biosciences has a 1 year low of $3.78 and a 1 year high of $19.15.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter.

Insider Activity

In other Pulse Biosciences news, CEO Burke Thomas Barrett purchased 10,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average cost of $8.56 per share, with a total value of $85,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $85,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 71.50% of the company’s stock.

Institutional Trading of Pulse Biosciences

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Pulse Biosciences by 28.8% during the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after acquiring an additional 189,227 shares in the last quarter. Griffin Asset Management Inc. boosted its stake in Pulse Biosciences by 15.7% in the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock valued at $2,616,000 after acquiring an additional 40,700 shares in the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Pulse Biosciences during the fourth quarter worth about $242,000. Cetera Advisors LLC acquired a new stake in shares of Pulse Biosciences during the first quarter worth about $109,000. Finally, Inspire Investing LLC lifted its holdings in shares of Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after purchasing an additional 10,039 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.